Immune checkpoint inhibitor-related pancreatitis: What is known and what is not
A 47-year-old man presented with a 1 week history of progressive fatigue and decreased appetite. He had stage IV oral squamous cell carcinoma and was treated with sintilimab, a programmed cell death protein 1 inhibitor, 22 months earlier. Laboratory work-up revealed significant elevation of bilirubi...
Main Authors: | Jiang Chunyan, Tang Wen, Yang Xu, Li Hongwei |
---|---|
Format: | Article |
Language: | English |
Published: |
De Gruyter
2023-06-01
|
Series: | Open Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1515/med-2023-0713 |
Similar Items
-
Pancreatic adverse events in patients treated with immune checkpoint inhibitors
by: Caroline Hana, et al.
Published: (2023-03-01) -
Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis
by: Yue Zhang, et al.
Published: (2022-04-01) -
A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer
by: Yue Hu, et al.
Published: (2023-04-01) -
Sintilimab-induced inflammatory myopathy in a patient with esophageal cancer: a case report
by: Guo Hong, et al.
Published: (2023-10-01) -
Ideas for the Diagnosis and Treatment of Multisystem Immune-related Adverse Events Caused by Immune Checkpoint Inhibitors
by: ZHANG Yanjing, SONG Xiaokun
Published: (2023-08-01)